

Hybrigenics books an exceptional revenue of EUR 1 million

Part of a redeemable advance from the French Ministry of Industry to perform protein interaction research is requalified as a grant

Paris, 28 August 2012 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments of proliferative diseases and specialised in protein interactions, today announces having reached an agreement with the French Ministry of Industry to requalify 70% of a 10-year old €1.37 million redeemable advance as a grant.

Hybrigenics received €1.37 million between 2002 and 2005 from the French Ministry of Industry to participate in a large academic and biotechnology collaborative programme comparing protein interactions in man and in the fruit fly, *Drosophila melanogaster*, as a model organism. The results of the 455 yeast two-hybrid screens performed by Hybrigenics during this programme resulted in contributions to 27 publications in top-level scientific journals such as Cell or Nature Cell Biology. They also provided the most detailed *Drosophila* protein interaction map to date, published in Genome Research (2005, 15:376-384) and freely available on-line at <http://pimr.hybrigenics.com/htmlFiles/interactionData/drosophila.html>

No original human therapeutic target homologous to a protein interaction in *Drosophila* was identified that Hybrigenics could patent to include in its R&D pipeline. This is the reason why Hybrigenics claimed the statute of partial success for the sponsored programme. An agreement has been reached with the French Ministry of Industry to reimburse 30% (€0.41 million) of the funds received (€1.37 million). As a consequence, the difference (€0.96 million) is requalified as a grant and will be booked as exceptional revenue.

“We are grateful to the Ministry of Industry for its understanding of the difference between highly successful fundamental protein interaction research in a model organism and applied therapeutic relevance for human health, which has remained elusive,” said Remi Delansorne, Hybrigenics’ CEO. *“This exceptional revenue of close to one million euro will significantly improve Hybrigenics’ P&L statement.”*

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.

Hybrigenics’ current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol is currently being studied in a clinical trial for the treatment of moderate-to-severe psoriasis. Oral inecalcitol is also planned to be tested in chronic lymphocytic leukemia patients. Oral inecalcitol has already shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere[®], which is the current gold-standard chemotherapeutic treatment for this indication.

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.

Hybrigenics Services SAS, a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform.

HYBRIGENICS

Press Release

HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics

Rémi Delansorne

CEO

Tel.: +33 (0)1 58 10 38 00

investors@hybrigenics.com

NewCap.

Financial communication

Axelle Vuillermet / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

hybrigenics@newcap.fr